Abstract

Multiple sclerosis (MS) is an immune-mediated disease improved by interferon-β (IFNβ) therapy. IFNβ may owe its anti-inflammatory property to its ability to induce interleukin-1 receptor antagonist (IL-1Ra) without triggering IL-1β synthesis in human monocytes. Furthermore, we recently demonstrated that IFNβ inhibits the production of IL-1β and tumor necrosis factor-α (TNF) in human monocytes activated by cellular contact with stimulated T cells, a mechanism which we suspected of playing an important part in the pathogenesis of chronic inflammatory diseases including MS. Here we compare modulatory effects of IFNβ on the production of proinflammatory cytokines (IL-1β, IL-1α, TNF, and IL-6) and IL-1Ra in human monocytes stimulated by lipopolysaccharides (LPS) and isolated plasma membranes of stimulated T cells (msHUT), which are likely to reflect monocyte activation in acute and chronic inflammation, respectively. In monocytes activated by either LPS or msHUT, IFNβ did not modulate the secretion of IL-1α and IL-6, but it enhanced the production of IL-1Ra in a dose-dependent manner. However, in monocytes activated by msHUT, the expression of cell-associated and intracellular IL-1α was inhibited by IFNβ, correlating with the inhibition of IL-1α transcript. IFNβ inhibited the expression (mRNA) and production (protein) of IL-1β and TNF, while enhancing those of IL-1Ra in monocytes activated by msHUT. In contrast, in monocytes activated by LPS, IFNβ enhanced the expression and production of IL-1β, TNF, and IL-1Ra, suggesting that it did not display anti-inflammatory properties in these conditions. This study demonstrates that IFNβ displays opposite effects depending on the type of activation of human monocytes, suggesting that it may affect different pathogenic mechanisms in opposite ways.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call